Product image of Kytril (Granisetron) supplied by GNH India

Kytril

Active Ingredient:
Granisetron
Origin:
EU

Kytril (Granisetron)

Granisetron, the active ingredient in Kytril, is a 5-HT3 receptor antagonist presented as an oral tablet for oral use. It prevents and treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult patients.
GNH India supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Atnahs Pharma Netherlands B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Kytril, a selective 5‑HT3 receptor antagonist, is used to control nausea and vomiting arising from several medical interventions.
  • Chemotherapy-induced nausea and vomiting: prevents and treats nausea and vomiting caused by cytotoxic chemotherapy.
  • Postoperative nausea and vomiting: reduces nausea and vomiting after surgical procedures.
  • Radiation therapy-induced nausea and vomiting: alleviates nausea and vomiting associated with radiation treatment.

How It Works

  • Granisetron selectively blocks peripheral and central 5‑HT3 receptors, inhibiting serotonin‑mediated stimulation of the chemoreceptor trigger zone and gastrointestinal vagal afferents. This antagonism prevents the neural signaling that triggers nausea and vomiting, providing antiemetic protection during chemotherapy, radiation, or postoperative periods.

Side Effects

Granisetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Headache
  • Constipation
  • Dizziness
  • Fatigue
  • Diarrhea
  • Abdominal discomfort

Serious or Rare Side Effects

  • QT interval prolongation
  • Severe allergic reactions (anaphylaxis, angioedema)
  • Serotonin syndrome when combined with serotonergic agents
  • Cardiac arrhythmias
  • Severe hypotension
  • Hepatic enzyme abnormalities

Precautions & Warnings

  • Before prescribing Kytril, clinicians should consider several safety aspects.
  • Assess cardiac history: evaluate risk of QT prolongation.
  • Monitor ECG: perform baseline and periodic ECGs in at-risk patients.
  • Review concomitant serotonergic drugs: avoid combinations that may trigger serotonin syndrome.
  • Use caution in hepatic impairment: adjust therapy based on liver function.
  • Consider renal function: monitor in severe renal disease.
  • Store below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Granisetron may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Other QT‑prolonging agents (e.g., quinidine, amiodarone)
  • Concurrent use of other 5‑HT3 antagonists
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
  • Serotonergic drugs (e.g., SSRIs, MAO inhibitors) increasing serotonin syndrome risk
  • Anticholinergic agents that may exacerbate constipation

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin, carbamazepine) reducing granisetron levels
  • Other antiemetics (e.g., metoclopramide) for additive effects
  • Diuretics causing electrolyte shifts that can affect cardiac repolarisation
  • Anesthetic agents that may influence QT interval

Frequently Asked Questions

Kytril contains granisetron, a selective 5‑HT3 receptor antagonist used to prevent and treat nausea and vomiting that occur after chemotherapy, radiation therapy, or surgical procedures. It is prescribed for adult patients who are at risk of emesis due to these medical interventions.

Granisetron blocks both peripheral and central 5‑HT3 receptors, which are activated by serotonin during emetic stimuli. By antagonizing these receptors, it stops the signal transmission from the gastrointestinal tract and the chemoreceptor trigger zone to the brain, thereby reducing the sensation of nausea and the act of vomiting.

The specific dose of Kytril is determined by the prescribing clinician based on the patient’s condition, treatment regimen, and individual health factors. Healthcare professionals adjust the dosage to achieve optimal antiemetic control while minimizing potential side effects.

Safety data for granisetron in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Clinicians must evaluate each case individually and discuss potential risks with the patient.

To request Kytril, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kytril (granisetron) belongs to the 5‑HT3 antagonist class, offering a rapid onset and a favorable side‑effect profile compared with older agents such as ondansetron or dolasetron. It is often preferred for patients who require strong antiemetic protection without significant sedation.

Kytril should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the tablet’s stability and potency throughout its shelf life.

Kytril is taken orally, typically as a tablet swallowed with water. The exact timing relative to chemotherapy, radiation, or surgery is directed by the prescribing clinician to ensure optimal antiemetic effect.

The most serious risks include QT interval prolongation, which can lead to cardiac arrhythmias, and severe allergic reactions such as anaphylaxis. Patients should be monitored for cardiac symptoms and signs of hypersensitivity, especially when taking other QT‑prolonging drugs.

Kytril is contraindicated in patients with known hypersensitivity to granisetron or any component of the formulation. It should also be avoided in individuals with a history of significant QT prolongation or those taking multiple QT‑prolonging medications without careful cardiac monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT